TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
Study: NCT03150446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible cystoscopy
Description: After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
Study: NCT03355534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Description: drug is intravenously infused to patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal dexmedetomidine
Description: drug is nasally given to patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous saline
Description: saline is given to patients intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous saline
Description: saline is given to patients intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal saline
Description: normal saline is given to patients nasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nasal saline
Description: normal saline is given to patients nasally
Study: NCT00786149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline without counseling
Description: Brief advice, one time during initial session
Study: NCT03298789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activation exercise
Description: Two series of 4 activation exercise will be included in the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: 7 series of static stretching
Description: 7 series of 4 20 seconds static stretches will be conducted.
Study: NCT02161081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myocardial CT perfusion
Description: Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
Study: NCT03298789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 series of static stretching
Description: 7 series of 4 20 seconds static stretches will be conducted.
Study: NCT02645136

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01266070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
Study: NCT03619642

Intervention type: OTHER
Group type: OTHER
Intervention: Robotic assessment of finger proprioception
Description: The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .

Intervention type: OTHER
Group type: OTHER
Intervention: Robotic assessment of finger proprioception
Description: The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .

Intervention type: OTHER
Group type: OTHER
Intervention: Robotic assessment of finger proprioception
Description: The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
Study: NCT02766517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Administered topically
Study: NCT03821181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIC group
Description: Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
Study: NCT01366950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intelligent physical activity
Description: 30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
Study: NCT01439009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Once-daily oral administration of one tolvaptan 15 mg tablet in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of tolvaptan
Description: Once-daily oral administration of one placebo tablet in the morning
Study: NCT02590250

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
Study: NCT04399044

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic muscle flap
Description: A muscle flap refers to taking an expendable muscle with its vascular supply and moving it to a new area. In this case, the investigators will take a muscle from the leg or abdomen that is redundant (other muscles perform the same function) and moving it to cover vascular grafts to provide healthy tissue to prevent infection.
Study: NCT03511326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Aminolaevulinate 16% Cream
Description: Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
Study: NCT00482807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT03259659

Intervention type: OTHER
Intervention: ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index
Description: In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.

Intervention type: OTHER
Intervention: ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index
Description: In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
Study: NCT03183336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge split interpositional block graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: decortication Onlay block graft
Study: NCT00525447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: 2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Up to 25 mg daily of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg administered weekly.
Study: NCT04688892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cupping
Description: dynamic cupping
Study: NCT03868150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Injection
Description: Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.

Intervention type: DRUG
Group type: OTHER
Intervention: Amiodarone Injection
Description: Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Rapid Atrial Pacing
Description: Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
Study: NCT02747329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme™ stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BuMA Supreme™ stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V/Prime stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience V/Prime stent
Study: NCT02161081

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial CT perfusion
Description: Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
Study: NCT03379532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI-NMES
Description: From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
Study: NCT01572480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
Study: NCT02691910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: 10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: 0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
Study: NCT00070109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03280199

Intervention type: OTHER
Group type: OTHER
Intervention: simulation types
Description: Different types of simulation interfaces and image acquisitions

Intervention type: OTHER
Group type: OTHER
Intervention: simulation types
Description: Different types of simulation interfaces and image acquisitions

Intervention type: OTHER
Group type: OTHER
Intervention: simulation types
Description: Different types of simulation interfaces and image acquisitions

Intervention type: OTHER
Group type: OTHER
Intervention: simulation types
Description: Different types of simulation interfaces and image acquisitions
Study: NCT03529838

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
Study: NCT01572480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by mouth (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
Study: NCT03402360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality rehabilitation group
Description: Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group rehabilitation
Description: Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training
Study: NCT00460525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: 3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
Study: NCT01329068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual consult
Description: regular individual consultations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group medical consult
Description: group medical consult
Study: NCT03993119

Intervention type: DRUG
Intervention: Non-vitamin K antagonist oral anticoagulant
Description: Non-vitamin K antagonist oral anticoagulant
Study: NCT01733524

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pet Fish
Description: Participants will receive a betta fish and the supplies to care for the fish for a one year time period.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Picture of a fish
Description: Participants will receive a picture of a betta fish.
Study: NCT03834480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Sacroiliac intra-articular injection
Description: At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided Sacroiliac intra-articular injection
Description: At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
Study: NCT03868150

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Rapid Atrial Pacing
Description: Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Rapid Atrial Pacing
Description: Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
Study: NCT03136965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Injection of autologous platelet rich plasma (PRP)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dry Needling
Description: This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry Needling - Sham
Description: This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.